SCHEMBL7207929

SCHEMBL7207929

CN(C)Cc1cc(C=CC(N)=O)ccc1Oc1ccc2c(c1)SCC2

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 14/20 0.53
HTR2A P28223 4/20 0.41
SLC6A2 P23975 4/20 0.39
SCN9A Q15858 2/20 0.35
KCNH2 Q12809 2/20 0.35
ALOX5 P09917 1/20 0.35
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SOS1 Q07889 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
SLC6A3 Q01959 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7207921 1.00 SLC6A4 (0.53) SLC6A4HTR2ASLC6A2SCN9AKCNH2
SCHEMBL7207176 0.80 SLC6A4 (0.53) SLC6A4HTR2ASLC6A2SCN9AKCNH2
SCHEMBL5878837 0.74 SLC6A4 (0.83) SLC6A4HTR2ASLC6A2KCNH2SLC6A3
SCHEMBL7207167 0.73 SLC6A4 (0.69) SLC6A4HTR2ASLC6A2KCNH2SOS1
SCHEMBL7065053 0.70 SLC6A4 (0.69) SLC6A4SLC6A2SOS1SLC6A3
SCHEMBL7213331 0.67 SLC6A4 (0.54) SLC6A4HTR2ASLC6A2SCN9AKCNH2
SCHEMBL7065906 0.66 SLC6A4 (0.65) SLC6A4HTR2ASLC6A2SCN9AKCNH2
SCHEMBL5878711 0.65 SLC6A4 (1.00) SLC6A4HTR2ASLC6A2KCNH2SLC6A3
SCHEMBL7206520 0.65 SLC6A4 (0.56) SLC6A4HTR2ASLC6A2KCNH2ALOX5
SCHEMBL7450097 0.64 KDM4E (0.66) KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610747-B2 Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder PFIZER INC. 2003-08-26 US disclosed